Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM

This is an open-label, phase 1b study to evaluate different approaches for CART-EGFR-IL13Ra2 dosing and further characterize the safety, feasibility, preliminary efficacy, and pharmacokinetics of CART-EGFR-IL13Ra2 cells in patients with EGFR-amplified glioblastoma that has recurred following prior radiotherapy.

NCT Number	NCT07209241
Lead Sponsor	University of Pennsylvania
Conditions	Recurrent Glioblastoma
Enrollment	12 participants
Start Date	2025-12-03
Primary Completion	2042-11-01 (estimated)
Study Completion	2042-11-01 (estimated)
Updated on ClinicalTrials.gov	2026-05-11